| 摘要 |
The present application concerns methods and tools for diagnosing prostate cancer and furthermore concerns methods and tools for prognosing disease progression of prostate cancer. The method comprises determining methylation level of the genes C1orf114, HAPLN3, AOX1, GAS6, ST6GALNAC3 and ZNF660 and comparing the result with a control, thus obtaining a response which is used for diagnosing a prostate cancer and/or for prognosing aspects of an individual suffering from prostate cancer. |
| 主权项 |
1. A method of determining if an individual has, or is at risk of developing prostate cancer, the method comprising the steps of:
a) providing a sample obtained from said individual; b) determining in the sample of a),
the methylation level, and/orthe transcriptional expression level, and/orthe translational expression level, of a panel of nucleotide sequences, wherein the panel comprises: I′) the nucleotide sequence of SEQ ID NO:3 (GAS6); or I″) a nucleotide sequence being complementary to SEQ ID NO: 3; or I″′) a nucleotide sequence having at least 90% sequence identity to any one of I′ or I″; or I″″) a fragment of any one of I′, I″ or I″′, wherein the fragment comprises at least 15 consecutive nucleotides of any one of I′, I″ or I″′; and II′) the nucleotide sequence of SEQ ID NO:4 (HAPLN3); or II″) a nucleotide sequence being complementary to SEQ ID NO: 4; or II″′) a nucleotide sequence having at least 90% sequence identity to any one of II′ or II″; or II″″) a fragment of any one of II′, II″ or II″′, wherein the fragment comprises at least 15 consecutive nucleotides of any one of I′, I″ or I″′; and III′) the nucleotide sequence of SEQ ID NO:1 (AOX1); or III″) a nucleotide sequence being complementary to SEQ ID NO: 1; or III″′) a nucleotide sequence having at least 90% sequence identity to any one of III′ or III″′; or III″″) a fragment of any one of III′, III″ or III″′, wherein the fragment comprises at least 15 consecutive nucleotides of any one of III′, III″ or III″′; and IV′) the nucleotide sequence of SEQ ID NO:2 (C1orf114); or IV″) a nucleotide sequence being complementary to SEQ ID NO: 2; or IV″′) a nucleotide sequence having at least 90% sequence identity to any one of IV′ or IV″; or IV″″) a fragment of any one of IV′, IV″ or IV″′, wherein the fragment comprises at least 15 consecutive nucleotides of any one of IV′, IV″ or IV″′; and V′) the nucleotide sequence of SEQ ID NO:5 (ST6GALNAC3); or V″) a nucleotide sequence being complementary to SEQ ID NO: 5; or V″′) a nucleotide sequence having at least 90% sequence identity to any one of V′ or V″; or V″″) a fragment of any one of V′, V″ or V″′, wherein the fragment comprises at least 15 consecutive nucleotides of any one of V′, V″ or V″′; and VI′) the nucleotide sequence of SEQ ID NO:6 (ZNF660); or VI″) a nucleotide sequence being complementary to SEQ ID NO: 6; or VI″′) a nucleotide sequence having at least 90% sequence identity to any one of VI′ or VI″; or VI″″) a fragment of any one of VI′, VI″ or VI″′, wherein the fragment comprises at least 15 consecutive nucleotides of any one of VI′, VI″ or VI″′; c) comparing
the methylation level, transcriptional level, and/or translational expression level of the sampled nucleotide sequence of b),withthe corresponding methylation level, transcriptional level, and/or translational expression level of a corresponding nucleotide sequence of a control sample,whereina methylation level being significantly higher than the methylation level of the control sample,and/ora transcriptional and/or a translational expression level being significantly lower than the transcriptional level of the control sample,is indicative of that the individual has, or is at risk of developing prostate cancer. |
